Jennifer L Ames1, Christine Ladd-Acosta2, M Daniele Fallin2, Yinge Qian3, Laura A Schieve4, Carolyn DiGuiseppi5, Li-Ching Lee6, Eric P Kasten7, Guoli Zhou7, Jennifer Pinto-Martin8, Ellen M Howerton2, Christopher L Eaton9, Lisa A Croen3. 1. Division of Research, Kaiser Permanente Northern California, Oakland, California. Electronic address: Jennifer.l.ames@kp.org. 2. Wendy Klag Center for Autism and Developmental Disabilities, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 3. Division of Research, Kaiser Permanente Northern California, Oakland, California. 4. National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia. 5. Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, Colorado. 6. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 7. Clinical and Translational Sciences Institute, Michigan State University, East Lansing, Michigan. 8. School of Nursing and Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 9. The Permanente Medical Group, Kaiser Permanente Medical Center, San Francisco, California.
Abstract
BACKGROUND: This study aims to clarify relationships of maternal psychiatric conditions and selective serotonin reuptake inhibitor (SSRI) use during preconception and pregnancy with risk of neurodevelopmental disorders in offspring. METHODS: We used data from the Study to Explore Early Development, a multisite case-control study conducted in the United States among children born between 2003 and 2011. Final study group classifications of autism spectrum disorder (ASD) (n = 1367), developmental delays or disorders (DDs) (n = 1750), and general population controls (n = 1671) were determined by an in-person standardized developmental assessment. Maternal psychiatric conditions and SSRI use during pregnancy were ascertained from both self-report and medical records. We used logistic regression to evaluate associations of ASD and DDs (vs. population controls) with maternal psychiatric conditions and SSRI treatment in pregnancy. To reduce confounding by indication, we also examined SSRI associations in analyses restricted to mothers with psychiatric conditions during pregnancy. RESULTS: Psychiatric conditions and SSRI use during pregnancy were significantly more common among mothers of children with either ASD or DDs than among population controls. Odds of ASD were similarly elevated among mothers with psychiatric conditions who did not use SSRIs during pregnancy (adjusted odds ratio 1.81, 95% confidence interval 1.44-2.27) as in mothers who did use SSRIs (adjusted odds ratio 2.05, 95% confidence interval 1.50-2.80). Among mothers with psychiatric conditions, SSRI use was not significantly associated with ASD in offspring (adjusted odds ratio 1.14, 95% confidence interval 0.80-1.62). Primary findings for DDs exhibited similar relationships to those observed with ASD. CONCLUSIONS: Maternal psychiatric conditions but not use of SSRIs during pregnancy were associated with increased risk of neurodevelopmental disorders in offspring.
BACKGROUND: This study aims to clarify relationships of maternal psychiatric conditions and selective serotonin reuptake inhibitor (SSRI) use during preconception and pregnancy with risk of neurodevelopmental disorders in offspring. METHODS: We used data from the Study to Explore Early Development, a multisite case-control study conducted in the United States among children born between 2003 and 2011. Final study group classifications of autism spectrum disorder (ASD) (n = 1367), developmental delays or disorders (DDs) (n = 1750), and general population controls (n = 1671) were determined by an in-person standardized developmental assessment. Maternal psychiatric conditions and SSRI use during pregnancy were ascertained from both self-report and medical records. We used logistic regression to evaluate associations of ASD and DDs (vs. population controls) with maternal psychiatric conditions and SSRI treatment in pregnancy. To reduce confounding by indication, we also examined SSRI associations in analyses restricted to mothers with psychiatric conditions during pregnancy. RESULTS: Psychiatric conditions and SSRI use during pregnancy were significantly more common among mothers of children with either ASD or DDs than among population controls. Odds of ASD were similarly elevated among mothers with psychiatric conditions who did not use SSRIs during pregnancy (adjusted odds ratio 1.81, 95% confidence interval 1.44-2.27) as in mothers who did use SSRIs (adjusted odds ratio 2.05, 95% confidence interval 1.50-2.80). Among mothers with psychiatric conditions, SSRI use was not significantly associated with ASD in offspring (adjusted odds ratio 1.14, 95% confidence interval 0.80-1.62). Primary findings for DDs exhibited similar relationships to those observed with ASD. CONCLUSIONS: Maternal psychiatric conditions but not use of SSRIs during pregnancy were associated with increased risk of neurodevelopmental disorders in offspring.
Authors: Alexander Viktorin; Rudolf Uher; Alexander Kolevzon; Abraham Reichenberg; Stephen Z Levine; Sven Sandin Journal: JAMA Psychiatry Date: 2017-10-01 Impact factor: 21.596
Authors: Hanan El Marroun; Tonya J H White; Noortje J F van der Knaap; Judith R Homberg; Guillén Fernández; Nikita K Schoemaker; Vincent W V Jaddoe; Albert Hofman; Frank C Verhulst; James J Hudziak; Bruno H C Stricker; Henning Tiemeier Journal: Br J Psychiatry Date: 2014-08-01 Impact factor: 9.319
Authors: Lisa D Wiggins; Ann Reynolds; Catherine E Rice; Eric J Moody; Pilar Bernal; Lisa Blaskey; Steven A Rosenberg; Li-Ching Lee; Susan E Levy Journal: J Autism Dev Disord Date: 2015-05
Authors: Elizabeth C Ailes; Regina M Simeone; April L Dawson; Emily E Petersen; Suzanne M Gilboa Journal: Birth Defects Res A Clin Mol Teratol Date: 2016-11
Authors: B M Anderson; N C Schnetz-Boutaud; J Bartlett; A M Wotawa; H H Wright; R K Abramson; M L Cuccaro; J R Gilbert; M A Pericak-Vance; J L Haines Journal: Neurogenetics Date: 2009-01-28 Impact factor: 2.660
Authors: Rebecca A Harrington; Li-Ching Lee; Rosa M Crum; Andrew W Zimmerman; Irva Hertz-Picciotto Journal: Pediatrics Date: 2014-04-14 Impact factor: 7.124
Authors: J Piven; G A Chase; R Landa; M Wzorek; J Gayle; D Cloud; S Folstein Journal: J Am Acad Child Adolesc Psychiatry Date: 1991-05 Impact factor: 8.829